---
schema_version: "secwatch.filing_event.v1"
accession: "0001040130-26-000016"
form_type: "8-K"
ticker: "PETS"
cik: "0001040130"
company_name: "PETMED EXPRESS INC"
filed_at: "2026-06-02T20:15:54+00:00"
generated_at: "2026-06-02T20:17:43.525036+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment

## Summary
- Q4 net sales $42.8M (down 15.6% YoY); FY net sales $179M (down 21.1%) on lower prescription sales.
- Q4 net loss narrowed to $4.1M ($0.19/sh) from $11.6M; FY net loss widened to $57.3M ($2.74/sh) from $6.3M.
- FY adjusted EBITDA -$15.4M (vs +$0.7M) due to $26.7M goodwill impairment and $4.5M severance/investigation.
- Board evaluated unsolicited buyout proposals at $4.00-$4.25/sh but opted not to pursue; open to future offers.
- Management cites sequential QoQ sales uptick, cost reductions, and B2B expansion (Rural King fulfillment deal).

## SEC filing metadata
- accession: 0001040130-26-000016
- form_type: 8-K
- ticker: PETS
- cik: 0001040130
- company_name: PETMED EXPRESS INC
- filed_at: 2026-06-02T20:15:54+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/pets-20260602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001040130-26-000016
- JSON: https://secwatch.observer/filing/0001040130-26-000016.json
- Plain text: https://secwatch.observer/filing/0001040130-26-000016.txt

## Source-grounded claims
- claim_id: 62fea84a056e32747ca7e3c5fd1c5d04a0a8b34e
  claim: PETMED EXPRESS INC reported fiscal year ended March 31, 2026 results: revenue $179.0 million, net income Net loss of $57.3 million, EPS $(2.74) per diluted share.
  evidence_excerpt: Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm
- claim_id: 6566c41bbc4e1f2ad99223926d25a8964ce2ef51
  claim: PETMED EXPRESS INC reported fourth quarter ended March 31, 2026 results: revenue $42.8 million, net income Net loss of $4.1 million, EPS $(0.19) per diluted share.
  evidence_excerpt: Net sales of $42.8 million compared to $50.8 million in the prior year period, a decrease of 15.6%, primarily driven by a decline in prescription medication sales. • Net loss of $4.1 million, or $(0.19) per diluted share, compared to a net loss of $11.6 million, or $(0.56) per diluted share, for the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.